查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1700049

2032 年血漿分餾療法市場預測：按類型、工藝、應用、最終用戶和地區進行的全球分析

Blood Plasma Derivatives Market Forecasts to 2032 - Global Analysis By Type, Process, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球血漿分餾衍生物市場預計在 2025 年達到 567.1 億美元，到 2032 年將達到 1,155.2 億美元，預測期內的複合年成長率為 10.7%。

人體血漿是血液的液體成分，是被稱為血漿分餾衍生物的專門藥物的來源。這些衍生物包括白蛋白、免疫球蛋白、凝血因子和α-1抗胰蛋白酶等必需蛋白質，常用於治療各種疾病。免疫力缺乏、血友病、Guillain-Barré二氏症候群等神經系統疾病都可以在它們的幫助下得到治療。血漿分餾是透過分餾獲得的，分餾是一種用於分離和精製用於醫療用途的特定蛋白質的技術。

根據世界血友病聯盟 (WFH) 的數據，全球每 10,000 人中約有 1 人患有血友病。

老年人口不斷增加

血漿療法需求不斷成長的主要驅動力是人口老化。老年人是血漿分餾的重要用戶，因為他們更容易患上凝血障礙、慢性肝病和免疫力缺乏等疾病。根據聯合國估計，到2050年，全球約有16億人，即六分之一的人口，年齡在65歲或以上。此外，感染疾病、心血管疾病和自體免疫疾病的風險也會隨著老齡化的成長而增加。許多此類疾病都是用血漿蛋白（如白蛋白和免疫球蛋白）治療的。

製造和加工成本過高

血漿分餾過程複雜且耗時，使得製造血漿衍生治療藥物的成本非常高。從血漿採集到最終產品的發布可能需要7到12個月的時間，導致營運成本很高。血漿分餾需要專門的設備、嚴格的品管測試和廣泛的儲存基礎設施來維持血漿蛋白的穩定性和功效。此外，生產少量成品需要幾公升血漿，這增加了總生產成本。例如，需要大約 130 次血漿捐贈才能生產足夠的靜脈注射免疫球蛋白 (IVIG) 來治療一名患者一年。

人們對免疫球蛋白和血漿療法的興趣日益濃厚

免疫力缺乏、神經系統疾病和自體免疫疾病的增加推動了對靜脈注射免疫球蛋白 (IVIG) 和皮下免疫球蛋白 (SCIG) 的需求。川崎病、慢性發炎性去髓鞘化多發性神經病變 (CIDP) 和原發性免疫力缺乏症 (PIDD) 等疾病需要長期免疫球蛋白治療。根據業內估計，全球對 IVIG 的需求每年以超過 8% 的速度成長，為市場創造了巨大的成長前景。此外，血漿衍生免疫球蛋白治療的適應症擴大至敗血症、多發性硬化症和阿茲海默症疾病，進一步提升了市場前景。

血漿捐獻短缺，供應有限

全球血漿供應高度依賴捐贈者的參與，而這取決於社會經濟因素、監管限制和公眾對血漿捐贈的態度。有關捐贈者補償的政策變化和倫理爭論可能會對依賴有償血漿捐獻模式的國家（如美國）造成混亂。此外，COVID-19 疫情凸顯了血漿採集的脆弱性，因為捐血大幅下降導致免疫球蛋白和凝血因子短缺。

COVID-19的影響：

COVID-19 疫情導致生產延遲、血漿採集中斷以及免疫球蛋白需求增加，對血漿分餾療法市場產生了重大影響。封鎖和社交隔離政策，尤其是在美國和歐洲等主要市場，導致血漿捐贈量下降，造成關鍵血漿衍生治療藥物的短缺。此外，由於針對 COVID-19 患者恢復期血漿療法的研究激增，導致產業重點暫時轉移，其他血漿衍生產品的供應鏈也受到了影響。

預計預測期內免疫球蛋白部分將達到最大程度的成長。

免疫球蛋白預計將在預測期內佔據最大的市場佔有率，因為它廣泛應用於治療自體免疫疾病、原發性和次發性免疫力缺乏缺陷以及Guillain-Barré二氏症候群和慢性脫髓鞘多發性神經炎（ CIDP）等神經系統疾病。免疫球蛋白產品的需求受到人口老化、免疫力缺乏盛行率上升以及血漿衍生治療方法知識不斷增加的推動。此外，靜脈注射的改進提高了患者的便利性和治療依從性。

預測期內層析法領域預計將以最高複合年成長率成長

由於色譜法在分離血漿蛋白方面具有卓越的效率、純度和精度，預計在預測期內層析法部分將出現最高的成長率。層析法在免疫球蛋白、白蛋白和凝血因子的生產中越來越受歡迎，因為與冷乙醇分餾等傳統技術相比，它具有更高的產量和特異性。對高純度血漿治療的需求不斷成長、層析法和離子交換層析法的改進以及對生物製藥研究的投資不斷增加，正在刺激層析法的快速應用。此外，由於層析法精製具有卓越的病原體去除能力，因此受到監管機構的青睞，從而進一步推動了市場的成長。

比最大的地區

預計北美地區將在預測期內佔據最大的市場佔有率。這是由於主要市場參與者的強大存在、高血漿捐贈率以及先進的醫療保健基礎設施。美國憑藉著完善的血漿捐獻設施和優惠的報銷政策，在該地區處於領先地位，並為全球血漿收集做出了重大貢獻。由於神經系統疾病、血友病和免疫系統疾病的盛行率不斷上升，以及人們對血漿治療方法的認知不斷提高，市場正在不斷成長。此外，北美在市場上的主導地位也是 FDA 強力的監管支持、血漿分餾技術的持續研究以及免疫球蛋白療法的廣泛採用的結果。

複合年成長率最高的地區：

預計亞太地區在預測期內的複合年成長率最高。這是由於免疫不全症的盛行率不斷上升、人們對血漿療法的認知不斷提高以及醫療成本不斷上升。政府對生技藥品和血漿分餾的支持、不斷成長的血漿採集計劃以及不斷改善的醫療基礎設施正在促進中國、印度和日本等國家的快速擴張。由於對凝血因子和免疫球蛋白的需求不斷成長，以及對先進精製技術的投資和藥品生產能力的擴大，市場正在不斷擴大。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球血漿分餾療法市場（按類型）

  • 白蛋白
  • 第八因子
  • 凝血因子IX
  • 免疫球蛋白
  • 高免疫球蛋白
  • 其他類型

6. 全球血漿分餾市場（按工藝）

  • 冷乙醇分餾
  • 過程
  • 層析法

7. 全球血漿分餾療法市場（按應用）

  • 血友病
  • 低丙種球蛋白血症
  • 免疫不全症
  • 血管性血友病
  • 其他用途

8. 全球血漿分餾療法市場（依最終用戶）

  • 醫院
  • 診所
  • 其他最終用戶

9. 全球血漿分餾療法市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Bayer AG
  • Fusion Health Care Pvt. Ltd.
  • Grifols, SA
  • Takeda Pharmaceutical Company
  • Sanofi
  • CSL Limited
  • LFB SA
  • Baxter International Inc.
  • Syntegon
  • Green Cross Corporation
  • Octapharma AG
  • Biotest AG
  • Kedrion Biopharma, Inc.
  • SK Plasma Co., Ltd.
  • Intas Pharmaceuticals Ltd.
Product Code: SMRC28952

According to Stratistics MRC, the Global Blood Plasma Derivatives Market is accounted for $56.71 billion in 2025 and is expected to reach $115.52 billion by 2032 growing at a CAGR of 10.7% during the forecast period. Human plasma, the liquid component of blood, is the source of specialized medicinal products known as blood plasma derivatives. Essential proteins like albumin, immunoglobulins, clotting factors, and alpha-1 antitrypsin are among these derivatives and are frequently used to treat a variety of illnesses. Immunodeficiencies, hemophilia, and neurological conditions like Guillain-Barre syndrome are all treated with their help. Fractionation, a technique used to isolate and purify particular proteins for medical applications, yields plasma derivatives.

According to the World Federation of Hemophilia (WFH), hemophilia affects approximately 1 in 10,000 people globally.

Market Dynamics:

Driver:

Increasing number of elderly people

A major factor in the rising demand for therapies derived from plasma is the aging population. The elderly are significant users of plasma derivatives because they are more susceptible to diseases like coagulation problems, chronic liver disease, and immunological deficiencies. Approximately 1.6 billion people, or one in six people worldwide, will be over 65 by 2050, according to UN estimates. Additionally, the risk of infections, cardiovascular conditions, and autoimmune diseases increases with age; many of these conditions are treated with plasma proteins such as albumin and immunoglobulins.

Restraint:

Exorbitant expenses for production and processing

The complicated and time-consuming plasma fractionation process makes the production of therapies derived from plasma extremely costly. Plasma collection and final product release can take seven to twelve months, which results in high operating costs. For plasma proteins to remain stable and effective, plasma fractionation necessitates specialized equipment, rigorous quality control testing, and a sizable storage infrastructure. Furthermore, the total cost of production is raised by the requirement for several liters of plasma to generate a small amount of the finished product. For instance, to make enough Intravenous Immunoglobulin (IVIG) to treat one patient for a year, about 130 plasma donations are needed.

Opportunity:

Growing interest in immunoglobulin and plasma treatments

Intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) are in high demand due to the increasing incidence of immune deficiencies, neurological conditions, and autoimmune diseases. Long-term immunoglobulin therapy is necessary for conditions like Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and primary immunodeficiency disorders (PIDD). Industry estimates indicate that the demand for IVIG has been rising globally at a rate of more than 8% per year, which has created significant growth prospects for the market. Moreover, prospects for the market are further enhanced by the extension of plasma-derived immunoglobulin treatment indications into conditions like sepsis, multiple sclerosis, and Alzheimer's disease.

Threat:

Lack of plasma donations and limitations on supply

The worldwide supply of plasma is largely reliant on donor participation, which varies depending on socioeconomic factors, regulatory limitations, and public attitudes regarding plasma donation. Policy changes and donor compensation ethical discussions could cause disruptions for nations like the US that depend on compensated plasma donation models. Additionally, the COVID-19 pandemic brought to light the vulnerability of plasma collection, as notable drops in donations resulted in immunoglobulin and clotting factor shortages.

Covid-19 Impact:

The COVID-19 pandemic had a major effect on the market for blood plasma derivatives because it caused delays in manufacturing, disruptions in plasma collection, and an increase in demand for immunoglobulins. Lockdowns and social distancing policies caused plasma donations to drop, particularly in important markets like the US and Europe, which resulted in a shortage of vital therapies derived from plasma. Furthermore, the supply chain for other plasma-derived products was also impacted by the brief shift in industry focus caused by the explosion in research on convalescent plasma therapy for COVID-19 patients.

The Immunoglobulin segment is expected to be the largest during the forecast period

The Immunoglobulin segment is expected to account for the largest market share during the forecast period, motivated by its extensive application in the treatment of autoimmune diseases, primary and secondary immunodeficiency's, and neurological disorders like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). The demand for immunoglobulin products has been driven by the growing number of elderly people, the increasing prevalence of immunodeficiency diseases, and the growing knowledge of plasma-derived treatments. Furthermore, improvements in immunoglobulin formulations for intravenous (IVIG) and subcutaneous (SCIG) administration have enhanced patient convenience and treatment compliance.

The Chromatography segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Chromatography segment is predicted to witness the highest growth rate, motivated by its exceptional efficiency, purity, and precision in plasma protein separation. Chromatography is becoming more and more popular for producing immunoglobulins, albumin, and coagulation factors because it provides superior yield and specificity compared to conventional techniques like cold ethanol fractionation. Its quick adoption is being fueled by the rising demand for high-purity plasma-derived treatments, improvements in affinity and ion-exchange chromatography, and rising investments in biopharmaceutical research. Moreover, the market growth of chromatography-based purification is further enhanced by regulatory bodies' preference for it because of its superior pathogen removal capabilities.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by a robust presence of major market players, high plasma donation rates, and sophisticated healthcare infrastructure. Because of its well-established plasma donation facilities and advantageous reimbursement policies, the United States leads the region and contributes significantly to global plasma collection. The market is growing due to the rising incidence of neurological diseases, hemophilia, and immune disorders, as well as increased awareness of therapies derived from plasma. Additionally, North America's dominant market position is also a result of the FDA's strong regulatory support, continuous research into plasma fractionation technologies, and widespread use of immunoglobulin treatments.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by the growing prevalence of immunodeficiency disorders, growing awareness of plasma-derived therapies, and rising healthcare costs. Government support for biologics and plasma fractionation, growing plasma collection programs, and better healthcare infrastructure are all contributing to the rapid expansion of nations like China, India, and Japan. The market is growing as a result of rising demand for coagulation factors and immunoglobulins, as well as investments in sophisticated purification technologies and growing pharmaceutical manufacturing capacities.

Key players in the market

Some of the key players in Blood Plasma Derivatives Market include Bayer AG, Fusion Health Care Pvt. Ltd., Grifols, S.A., Takeda Pharmaceutical Company, Sanofi, CSL Limited, LFB S.A., Baxter International Inc., Syntegon, Green Cross Corporation, Octapharma AG, Biotest AG, Kedrion Biopharma, Inc., SK Plasma Co., Ltd. and Intas Pharmaceuticals Ltd.

Key Developments:

In February 2025, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). The terms of the transaction remain unchanged from those previously announced and closing is expected in the second quarter of 2025 at the earliest.

In January 2025, Bayer announced that the company has signed a new exclusive distribution agreement with UK-based Ecospray to market a biological liquid nematicide sourced from garlic. The product presents a biological alternative to traditional synthetic chemical nematicides in vegetable and potato crops, and will be marketed in the European Union under the new name Velsinum(TM).

In June 2024, Takeda announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Types Covered:

  • Albumin
  • Factor VIII
  • Factor IX
  • Immunoglobulin
  • Hyperimmune Globulin
  • Other Types

Processes Covered:

  • Cold Ethanol Fractionation
  • Heat Treatment
  • Chromatography

Applications Covered:

  • Hemophilia
  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Von Willebrand'S Disease
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Blood Plasma Derivatives Market, By Type

  • 5.1 Introduction
  • 5.2 Albumin
  • 5.3 Factor VIII
  • 5.4 Factor IX
  • 5.5 Immunoglobulin
  • 5.6 Hyperimmune Globulin
  • 5.7 Other Types

6 Global Blood Plasma Derivatives Market, By Process

  • 6.1 Introduction
  • 6.2 Cold Ethanol Fractionation
  • 6.3 Heat Treatment
  • 6.4 Chromatography

7 Global Blood Plasma Derivatives Market, By Application

  • 7.1 Introduction
  • 7.2 Hemophilia
  • 7.3 Hypogammaglobulinemia
  • 7.4 Immunodeficiency Diseases
  • 7.5 Von Willebrand'S Disease
  • 7.6 Other Applications

8 Global Blood Plasma Derivatives Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Other End Users

9 Global Blood Plasma Derivatives Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Bayer AG
  • 11.2 Fusion Health Care Pvt. Ltd.
  • 11.3 Grifols, S.A.
  • 11.4 Takeda Pharmaceutical Company
  • 11.5 Sanofi
  • 11.6 CSL Limited
  • 11.7 LFB S.A.
  • 11.8 Baxter International Inc.
  • 11.9 Syntegon
  • 11.10 Green Cross Corporation
  • 11.11 Octapharma AG
  • 11.12 Biotest AG
  • 11.13 Kedrion Biopharma, Inc.
  • 11.14 SK Plasma Co., Ltd.
  • 11.15 Intas Pharmaceuticals Ltd.

List of Tables

  • Table 1 Global Blood Plasma Derivatives Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
  • Table 4 Global Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
  • Table 5 Global Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
  • Table 6 Global Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
  • Table 7 Global Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
  • Table 8 Global Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 9 Global Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
  • Table 10 Global Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
  • Table 11 Global Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
  • Table 12 Global Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
  • Table 13 Global Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
  • Table 14 Global Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
  • Table 15 Global Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
  • Table 16 Global Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
  • Table 17 Global Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
  • Table 18 Global Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 19 Global Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 21 Global Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 22 Global Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 23 North America Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
  • Table 24 North America Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
  • Table 25 North America Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
  • Table 26 North America Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
  • Table 27 North America Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
  • Table 28 North America Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
  • Table 29 North America Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
  • Table 30 North America Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 31 North America Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
  • Table 32 North America Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
  • Table 33 North America Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
  • Table 34 North America Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
  • Table 35 North America Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
  • Table 36 North America Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
  • Table 37 North America Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
  • Table 38 North America Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
  • Table 39 North America Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
  • Table 40 North America Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 41 North America Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
  • Table 42 North America Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 43 North America Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 44 North America Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 45 Europe Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
  • Table 46 Europe Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
  • Table 47 Europe Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
  • Table 48 Europe Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
  • Table 49 Europe Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
  • Table 50 Europe Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
  • Table 51 Europe Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
  • Table 52 Europe Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 53 Europe Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
  • Table 54 Europe Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
  • Table 55 Europe Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
  • Table 56 Europe Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
  • Table 57 Europe Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
  • Table 58 Europe Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
  • Table 59 Europe Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
  • Table 60 Europe Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
  • Table 61 Europe Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
  • Table 62 Europe Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 63 Europe Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
  • Table 64 Europe Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 65 Europe Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 66 Europe Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 67 Asia Pacific Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
  • Table 68 Asia Pacific Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
  • Table 69 Asia Pacific Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
  • Table 70 Asia Pacific Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
  • Table 71 Asia Pacific Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
  • Table 72 Asia Pacific Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
  • Table 73 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
  • Table 74 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 75 Asia Pacific Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
  • Table 76 Asia Pacific Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
  • Table 77 Asia Pacific Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
  • Table 78 Asia Pacific Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
  • Table 79 Asia Pacific Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
  • Table 80 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
  • Table 81 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
  • Table 82 Asia Pacific Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
  • Table 83 Asia Pacific Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
  • Table 84 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 85 Asia Pacific Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
  • Table 86 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 87 Asia Pacific Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 88 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 89 South America Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
  • Table 90 South America Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
  • Table 91 South America Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
  • Table 92 South America Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
  • Table 93 South America Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
  • Table 94 South America Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
  • Table 95 South America Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
  • Table 96 South America Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 97 South America Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
  • Table 98 South America Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
  • Table 99 South America Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
  • Table 100 South America Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
  • Table 101 South America Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
  • Table 102 South America Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
  • Table 103 South America Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
  • Table 104 South America Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
  • Table 105 South America Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
  • Table 106 South America Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 107 South America Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
  • Table 108 South America Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 109 South America Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 110 South America Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 111 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
  • Table 112 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
  • Table 113 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
  • Table 114 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
  • Table 115 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
  • Table 116 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
  • Table 117 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
  • Table 118 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 119 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
  • Table 120 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
  • Table 121 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
  • Table 122 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
  • Table 123 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
  • Table 124 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
  • Table 125 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
  • Table 126 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
  • Table 127 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
  • Table 128 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 129 Middle East & Africa Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
  • Table 130 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 131 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 132 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)